Palisade Bio, a clinical-stage biopharmaceutical company, announced that its CEO and President will participate in the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. They will hold one-on-one meetings with investors to discuss the company's clinical development strategy and progress with its lead drug candidate, PALI-2108, aimed at treating inflammatory bowel diseases like ulcerative colitis and Crohn's disease. The company is advancing PALI-2108 towards Phase 2 clinical trials following encouraging Phase 1 results. This event is important as it provides updates on Palisade Bio's efforts to develop improved oral therapies for chronic inflammatory and fibrotic diseases.
Regions Financial Corporation's stock surged to a 52-week high of $32.47 following a Jefferies analyst upgrade raising the price target to $32. The bank reported strong Q2 2026 adjusted earnings of $0.68 per share, beating estimates of $0.64, driven ...
Several key stocks fell significantly due to company-specific issues. Intuitive Surgical's shares dropped 14.15% despite strong earnings because of slower growth in surgical procedures, impacting related leveraged ETFs. REGENXBIO's stock fell 11.7% a...
DBV Technologies has filed a prospectus with the U.S. SEC to renew its At-The-Market (ATM) offering program, allowing it to raise up to $150 million by selling American Depositary Shares (ADSs). The funds will primarily support expanding manufacturin...
Glencore has amended and restated its $5 million convertible loan agreement with Tantalex Lithium Resources Corporation, splitting the loan into three facilities with adjusted terms and interest rates. The amended agreement includes a 1% gross revenu...
A Race Against Blindness, an Arizona nonprofit, has launched its first electric vehicle fundraiser featuring a 2025 Volkswagen ID. Buzz and $20,000 cash as the grand prize. Running from July 13 to 26, the campaign aims to raise funds for clinical tri...
